Nevro
Corp. (NYSE: NVRO) widened losses for the first quarter but revenue soared
and the Food and Drug Administration approved the company's Senza spinal
cord stimulation system. Shares of the medical device maker leaped $7.97 to close at $53.33.
FDA approves Nevro's Senza
May 11, 2015 at 18:46 PM EDT
